Disconnect between in vitro and in vivo efficacy of the MPS1 inhibitor NTRC 0066-0 against glioblastoma
Mark C. de Gooijer(Manchester Academic Health Science Centre), Olaf van Tellingen(The Netherlands Cancer Institute), J.H. Beijnen(Oncode Institute), Ping Zhang(Oncode Institute), Irena Bočkaj(University of Groningen), Levi C.M. Buil(Cancer Genomics Centre), Laura E. Kuil(The Netherlands Cancer Institute), Ana Maia(The Netherlands Cancer Institute), Margarita Espitia-Ballestas(The Netherlands Cancer Institute), Daria M. Fedorushkova(Dutch Cancer Society), Hilal Çolakoğlu(Oncode Institute), Ceren H. Çitirikkaya(The Netherlands Cancer Institute)
Cited by 0
Related Papers
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Homozygous Mutations in CSF1R Cause a Pediatric-Onset Leukoencephalopathy and Can Result in Congenital Absence of Microglia
|The American Journal of Human Genetics|2019|263
ABCB1, ABCG2, and PTEN Determine the Response of Glioblastoma to Temozolomide and ABT-888 Therapy
|Clinical Cancer Research|2014|147